linjc16/ctgov huggingface dataset:
Quantification and Repeatability of Magnetic Stimulation

Study Overview
=================
Brief Summary
-----------------
In this project the quantification and the repeatability of responses to rapid bilateral magnetic stimulation of the phrenic nerves will be investigated in healthy humans.

Official Title
-----------------
Quantification and Repeatability of Responses to Rapid Bilateral Magnetic Stimulation of the Phrenic Nerves

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Magnetic phrenic nerve stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy non-smoking normal lung function body mass index: 18.5-29.9 kg/m2 able to communicate in english willing to adhere to study rules Exclusion Criteria: acute illness or chronic conditions of the gastrointestinal tract, and health conditions affecting metabolism, the cardiovascular or the respiratory system, or sleep intake of medications affecting metabolism, the cardiovascular, the neuromuscular or the respiratory system, or sleep any metal or electronics inside of the body presence of cardiac pacemaker, implanted defibrillators or implanted neurostimulators history of seizures or epilepsy tatoos on the stimulation sites previous enrolment in this study for women: pregnancy, breastfeeding, or intention to become pregnant during the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bilateral rapid magnetic stimulation of the phrenic nerves<br>Each participant will be tested on three different days with optimal settings for bilateral rapid magnetic stimulation of the phrenic nerves established on visit 1 and then repeated on visits 2 and 3. | Other: Magnetic phrenic nerve stimulation<br>* The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities. On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diaphragm contractility | Transdiaphragmatic pressure changes, i.e. changes in esophageal and gastric pressures, will be measured by a pressure transducer connected to balloon-catheters. | Continuously measured from 10 sec before until 10 sec after each stimulation. One stimulation lasts for approx. 1 sec |
Biomarkers in Patients Hospitalized With Suspected Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The concentration of troponins in plasma is used for diagnosing acute myocardial infarction. Different types of heart-specific troponins can be measured and with different analytical methods. The primary aim of this study is to evaluate the diagnostic characteristics of a new analytical method for measuring troponin I in diagnosing acute myocardial infarction.

Official Title
-----------------
Biomarkers in Patients Hospitalized With Suspected Acute Myocardial Infarction

Conditions
-----------------
Myocardial Infarction, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hospitalized at St. Olavs hospital blood sampled for troponin analysis due to suspicion of acute myocardial infarction without ST-elevations on ECG less than 4 hours after admitted to the hospital Exclusion Criteria: residency outside Norway does not understand Norwegian

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute myocardial infarction according to the 4th universal definition of myocardial infarction | Metric: Yes/No | Before discharge from hospital, a median of 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Days between hospital discharge and death | Metric: Days. The secondary outcome measures will be combined into a composite endpoint reflecting the time between hospital admission and the first secondary outcome measure | Within 30 days after hospital discharge | 
| Days between hospital discharge and acute myocardial infarction according to the 4th universal definition of myocardial infarction | Metric: Days. | Within 30 days after hospital discharge | 
| Days between hospital discharge and coronary revascularization | Metric: Days | Within 30 days after hospital discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Troponin I, Myocardial Infarction, Sensitivity and Specificity, Receiver operation characteristics curve, Biomarkers
Comparison of Outcomes Between Biceps Tenotomy and Tenodesis in the Treatment of the Long Head of the Biceps Pathology

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine what the different outcomes are for biceps tenodesis and tenotomy in the treatment of the long head of the biceps pathology.

Official Title
-----------------
Biceps Tenotomy or Tenodesis in Treating Long Head of the Biceps Pathology: a Prospective Randomized Controlled Trial

Conditions
-----------------
Chronic Refractive Bicipital Pain

Intervention / Treatment
-----------------
* Procedure: Biceps tenotomy
* Procedure: Biceps tenodesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with chronic refractive bicipital pain Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Biceps tenodesis<br>32 subjects in the study will receive biceps tenodesis as a surgical intervention | Procedure: Biceps tenodesis<br>* Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.<br>|
| Active Comparator: Biceps tenotomy<br>32 subjects in the study will receive biceps tenotomy as a surgical intervention | Procedure: Biceps tenotomy<br>* A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| American Shoulder and Elbow Surgeons (ASES) Shoulder Score | The scale measures pain from 0 to 10 and also includes a questionnaire for assessing the activity of daily living. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EuroQol EQ-5D | The questionnaire measures mobility, ability to care for self, ability to perform usual activities, pain/discomfort, and anxiety/depression | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biceps tenodesis, biceps tenotomy, biceps tendonitis, biceps inflammation, shoulder surgery
Study of Depression, Peptides, and Steroids in Cushing's Syndrome

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Study the relationship between dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and disorders of mood, vegetative function, and cognition in patients with Cushing's disease. II. Identify subgroups of patients with Cushing's disease who differ in the presence and severity of the depressive syndrome, and uncover HPA axis dysregulation differences among them using corticotropin-releasing hormone, metyrapone, and dexamethasone challenge testing.

Detailed Description
-----------------
PROTOCOL OUTLINE: All patients receive a psychiatric evaluation at baseline, as well as assessments of plasma adrenocorticotropin, beta lipotropin, beta endorphin, and cortisol, and urinary cortisol. Peptide and steroid assays are performed, alone and in response to corticotropin-releasing hormone, metyrapone, and dexamethasone. Patients are given sleep electroencephalograms at baseline and 1 year following treatment. A weight maintenance diet is prescribed for all patients.

Conditions
-----------------
Cushing's Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: Patients aged 20 to 60 with spontaneous active Cushing's syndrome At least 2 weeks since medication with psychoactive effects or influence on cortisol metabolism by hepatic hydroxylating enzyme induction Antihypertensives allowed for severe hypertension No barbiturates No phenytoin

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cushing's syndrome, endocrine disorders, rare disease
NICU-TECH RM9L-RS Probe ME Feasibility Study

Study Overview
=================
Brief Summary
-----------------
Use of a new ultrasound device designed for babies to look at the catheters in veins and arteries as well as the blood vessel itself. An observational study to assess the the clinicians perception of the ultrasound image quality as a tool to detect catheters in vessels.

Detailed Description
-----------------
The intent of the study is to confirm the maximum penetration of the NICU-Tech RM9L-RS probe. The investigators collected images on patients with PIV (Peripheral Intra Venous)/PAC (Peripheral Arterial Catheter) and central line catheters. The investigators collected images of deep vessel structures for offline processing to improve NICU-Tech algorithms for vessel segmentation.

Official Title
-----------------
NICU-TECH RM9L-RS Probe ME Feasibility Study

Conditions
-----------------
Neonates

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonates that are 23 gestational weeks at birth (and greater than 500 grams) to a 6 month old born infant at term (maximum weight 7 kg) who already have one or more lines placed (PIV/PAC/UVC/UACs/PICC) as part of their medical care. NO INFANT WILL HAVE A LINE PLACE FOR THE PURPOSE OF THIS STUDY Exclusion Criteria: Neonates that are less than 23 gestational weeks at birth Neonates that are 23 gestational weeks at birth but are less than 500 grams in weight Patients weighing more than 7 kg.-Patients older than 6 months

Ages Eligible for Study
-----------------
Minimum Age: 23 Weeks
Maximum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Arm 1: observational ultrasound<br>Collection of image data with the ultrasound probe. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants That Fulfilled All Study Procedures. | Acquisition of basic images and video were obtained from study participants who already have one or more catheters in place. | 1 day (day of procedure) | 
| Vessel Penetration of NICU-Tech RM9L-RS Probe | The algorithmic depth of vessel penetration will be collected. | 1 day (day of procedure) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neonates and infants, from the 23-week gestational (0.5 kg), up to a 6 month old born at term (7 kg), for whom the PIV,, PAC, UAC, UVC or PICC catheter insertion is medically, indicated.
Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa

Study Overview
=================
Brief Summary
-----------------
6 monthly treatments with IPL laser in patients with Hidradenitis Suppurativa. The effect in measured on several severity scores.

Detailed Description
-----------------
Patient suffering from bilateral HS in the axilla or groin area are threated with IPL laser monthly for 6 months. Patients are randomized to treatment in either left or right side, the other side works as control. No sham treatment, but observers are blinded.

Official Title
-----------------
The Effect of Intense Pulsed Light Assisted Hair Removal Therapy on Mild and Moderate Cases of Hidrosadenitis Suppurativa

Conditions
-----------------
Hidradenitis Suppurativa, Acne Inversa

Intervention / Treatment
-----------------
* Other: IPL laser
* Other: No sham treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bilateral HS in the axilla or groin area Fitzpatrick skin type I-II Exclusion Criteria: Pregnant Unable to understand or communicate with study personnel

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Patients are randomized to treatment in either left or right side, using the other side as control.
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study group<br>Patients are randomized to treatment of either right or left side. The other side works as control | Other: IPL laser<br>* IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type<br>|
| Sham Comparator: Comparator Group<br>Patients are randomized to treatment in either right or left side. The other side works as control | Other: No sham treatment<br>* The treatment is slightly painful, and noisy. Sham treatment impossible<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HiScore | 50 % reduction in abcesses and draining fistual | After 6 treatments i.e. 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sartorius score | HS severity score | after 6 treatments i.e. 6 months | 
| Physician global assesment | HS severity score | after 6 treatments i.e. 6 months |
Vancomycin Serum Concentrations in Pediatric Oncology Patients Under Intensive Care

Study Overview
=================
Brief Summary
-----------------
Observational protocol to analyse routine vancomycin serum levels of patients under intensive care and to obtain percentage of patients that achieve therapeutic values.

Official Title
-----------------
Vancomycin Serum Concentrations in Pediatric Oncology Patients Under Intensive Care

Conditions
-----------------
Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized pediatric oncology patients Patients under vancomycin treatment
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study to Determine if Monitoring of Labor Shortens the Time to Delivery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the hypothesis that using the BirthTrack for management of labor shortens the time to delivery and thus improves both maternal and perinatal outcomes.

Official Title
-----------------
Management of Labor Using the BirthTrack Computerized Labor Monitoring System

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Device: BirthTrack


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient must be ≥ 18 years old Nulliparous Singleton fetus in vertex presentation Gestational age 36-0/7 or more Reassuring fetal heart tracing Exclusion Criteria: Any significant medical condition which in the Investigator's opinion may interfere with the patient's optimal participation in the study Low lying placenta (edge 3cm or less from cervix) Known or suspected fetal or maternal infection Maternal thrombocytopenia (platelet count <100,000) Maternal bleeding disorder Women with previous uterine surgery Known major fetal malformation Suspected fetal growth restriction (EFW<10th percentile) Subjects with significant psychiatric history Major maternal morbidity (e.g. major cardiac disease) Subjects with indication for immediate delivery Limit on cervical dilation (e.g., up to 7 cm.) Prolonged rupture of membranes (i.e., > 24 hours)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BirthTrack Monitor<br> | Device: BirthTrack<br>* Measurement of cervical dilation and head station<br>* Other names: Computerized Labor Monitoring System;|
| No Intervention: Control - no BirthTrack Monitor<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Shortened time to vaginal delivery |  | Length of labor until delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nulliparous women in spontaneous labor
Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes

Study Overview
=================
Brief Summary
-----------------
This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.

Official Title
-----------------
A Multi-Center, Double-Blind, Randomized Study Comparing the Efficacy of Combination Therapy of Eprosartan Respectively Ramipril With Low-Dose Hydrochlorothiazide and Moxonidine on Blood Pressure Levels in Patients With Hypertension and Associated Diabetes Mellitus Type 2

Conditions
-----------------
Hypertension, Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: eprosartan/HCTZ


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: essential hypertension, diabetes type 2 Exclusion Criteria: severe cardiovascular disease, grade 3 hypertension, secondary hypertension, abnormal liver enzymes

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: eprosartan/HCTZ|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure reduction |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of responder rates |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, comparator trial, hypertension, blood pressure